Skip to main content
Premium Trial:

Request an Annual Quote

Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer

NEW YORK – Genecast said on Monday that it will launch a clinical trial to assess whether its qPCR-based liquid biopsy test can detect EGFR mutations in early-stage non-small cell lung cancer, or NSCLC, patients.

The Seoul, South Korea-based diagnostics firm developed its liquid biopsy assay using allele-discriminating priming system, or ADPS, technology, which it says allows for simpler and faster diagnostics than other liquid biopsy technologies due to its high detection sensitivity.

In a clinical trial conducted at the Samsung Medical Center, the firm will now evaluate how well the test reflects the results of tumor-based EGFR mutation testing for patients with stage 1B to 3A NSCLC.

Should the trial validate the ADPS liquid biopsy's ability to pick up somatic EGFR mutations in this early-stage NSCLC population, Genecast hopes it will become a useful tool to guide anti-EGFR treatment decisions. Specifically, detecting EGFR mutations at the onset for early-stage NSCLC could identify patients eligible for adjuvant or neoadjuvant EGFR inhibitors such as osimertinib (AstraZeneca's Tagrisso), which has recently received regulatory approval in multiple countries — including the US and China — for early-stage NSCLC following surgical resection.

AstraZeneca is also evaluating neoadjuvant osimertinib — that is, administering the therapy prior to surgical resection — in a Phase III clinical trial for EGFR-mutated early-stage NSCLC. Neoadjuvant treatment with an EGFR TKI necessitates EGFR mutation detection prior to surgery, which, for early-stage patients without distant metastases, is much more feasible via blood-based diagnostics than tissue biopsy.

"With the recent FDA approval of osimertinib as an adjuvant therapy for early-stage NSCLC, the early diagnosis of this cancer using liquid biopsies is receiving attention again," Byungchul Lee, Genecast's chief technical officer, said in a statement. "If liquid biopsies can diagnose not only metastatic lung cancer, but also operable early-stage lung cancer, then they are likely to improve the survival rates of NSCLC patients."

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.